

Update on the West Nile virus epidemiological situation and surveillance plans for 2024

Tamas Bakonyi (ECDC)
Giusi Amore (EFSA)


PAFF Committee meeting, Brussels - online, 16 May 2024



West Nile virus infections in humans



- High-impact mosquito-borne disease in humans in the EU/EEA
 - Broad geographic distribution
 - Most cases are locally acquired
 - Severe manifestations, case fatality ~10%
- Apparent changes in the epidemiological trends in the past years
 - The number of reported, locally acquired human WNV infections in the EU/EEA exceeded 700 cases annually in 2022-2023
 - Longer transmission seasons
- The first reported human case in 2024:
 - Seville, Andalusia, Spain
 - Date of (CNS) symptoms onset: 01 March



Enhanced seasonal WNV infection surveillance in humans in the EU/EEA



- Purpose: To inform blood safety authorities about risk areas of locally acquired
 West Nile virus infection in the EU/EEA and EU-neighbouring countries
- Legal basis:
 - Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components
 - Commission Directive 2014/110/EU of 17 December 2014 amending Directive 2004/33/EC
 as regards temporary deferral criteria for donors of allogeneic blood donations

Brucellosis (*) 2 years following the date of full recovery Osteomyelitis 2 years after confirmed cured nitions s 2 years following the date of confirmed cured Q fever (*) Syphilis (*) 1 year following the date of confirmed cured Toxoplasmosis (*) 6 months following the date of clinical recovery ive don Tuberculosis 2 years following the date of confirmed cured ishment

West Nile Virus (WNV) (*)

28 days after leaving an area with ongoing to to humans

Blood and blood components imported from third coun-

Article 4

20.12.2014 EN Official Journal of the European Union

COMMISSION DIRECTIVE 2014/110/EU

L 366/81

of 17 December 2014

amending Directive 2004/33/EC as regards temporary deferral criteria for donors of allogeneic blood donations

(Text with EEA relevance)

THE EUROPEAN COMMISSION.

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC (1), and in particular point (d) of the second paragraph of Article 29 thereof,

Whereas:

Directiv

nmittee

- (1) Point 2.2 of Annex III to Commission Directive 2004/33/EC (2) lays down temporary deferral criteria for donors with an infectious illness or donors leaving an area where an infectious illness is present.
- (2) Point 2.2.1 of Annex III to Directive 2004/33/EC establishes a deferral period for prospective donors of 28 days after leaving an area with ongoing transmission of West Nile Virus (WNV) to humans.
- (3) Recent scientific evidence has demonstrated that a temporary deferral of such prospective donors is not required if a Nucleic Acid Test (NAT) was carried out and the test was negative.
- (4) Therefore, the Member States should be given the option to apply such a test, if they want to replace the temporary deferral
- (5) The measures provided for in this Directive are in accordance with the opinion of the Committee set up by Directive 2002/98/EC.

HAS ADOPTED THIS DIRECTIVE:

Article 1

The deferral criterion for West Nile Virus set out in the table (second column, last row) of point 2.2.1 of Annex III to Directive 2004/33/EC is replaced by the following:

'28 days after leaving a risk area of locally acquired West Nile Virus unless an individual Nucleic Acid Test (NAT) is negative

Article 2

1. Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with this Directive by 31 December 2015 at the latest. They shall forthwith communicate to the Commission the text of those provisions.

When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the accession of their official publication. Member States shall determine have auch reference in to be

Enhanced seasonal WNV infection surveillance in <a href="https://humans.ncbi.nlm.ncb



- Surveillance is done by the Member States; data are reported to ECDC through TESSy; case-based data is expected, according to the EU case definition.
- Weekly reporting to ECDC between the beginning of June and the end of November
- Place of infection (NUTS3 / GAUL 1) and date of infection are particularly important metadata
- ECDC publishes surveillance data
- On a weekly basis: to provide necessary info for SoHO authorities
- On a monthly basis: to provide enhanced analysis and assessment

Surveillance of West Nile virus infections: weekly




Weekly data collection on human cases, through TESSy

Weekly updates on ECDC website, with a focus on distribution of <u>human</u> cases










Timely inform SoHO authorities for implementation of the temporary deferral for donors of allogenic blood donations / blood testing for WNV



Surveillance of West Nile virus infections: monthly



Weekly data collection on human cases, through TESSy






Collection of animal cases (equids and birds), through ADIS





<u>Monthly</u> enhanced analysis on ECDC website






Inform public health and veterinary authorities and provide a risk assessment of the situation

One Health approach: reporting and co-visualisation of data on WNF outbreaks in equine and avian hosts reported in ADIS





WNV – surveillance in animals



- WNV surveillance in animals involves mostly passive surveillance, including surveillance based on the diagnosis of neuro-invasive cases in equids, but some countries implement active surveillance of equids and/or captive birds and/or wild birds
- WNV data from annual surveillance and monitoring activities (number of tested and positive animals based on registered methods) reported to EFSA by EU MSs and non-MSs in accordance with **Directive 2003/99/EC (Annex I, part B)**
- Number of outbreaks of equine and avian WNV reported to ADIS according with CIR (EU) 2020/2002
 - o Primary outbreaks to be notified to Commission and the other MSs within 24 hours
 - o Secondary outbreaks to be notified to Commission on the first working day of each week covering the previous week



WNV - joint EFSA-ECDC EU One Health Zoonoses Report


WNV surveillance findings in humans and animals (birds and equids) in EU are summarized in a dedicated chapter of the **joint EFSA-ECDC One Health Zoonoses** (EUOHZ) Report



Geographical distribution of locally acquired West Nile virus infections among humans (NUTS 3 level) and outbreaks notified to ADIS among equids and birds (X,Y coordinates) across the EU, 2022 transmission season.









WNV - Outbreaks in birds and equidae 2013-2024 (source: ADIS)

VetsqEUROPEAN FOOD SAFETY AUTHORITY

Data reported by EU-MSs *



Observed seasonal pattern: July-November (peak in September)



WNV – surveillance in animals 2013-2024



EQUIDAE

					•							
Year	Months (only shown when data reported)											
	January	March	April	May	June	July	August	September	October	November	December	Grand Total
2013						2	18	23	21	15		79
2014	1				1		3	11	13	2		31
2015						1	7	39	39	6		92
2016						2	26	68	68	8	1	173
2017						8	22	24	17	6	7	84
2018					1	11	109	109	48	12	2	292
2019	2	1		1		7	10	37	31	7	3	99
2020	1					1	52	84	44	7	1	190
2021					1		6	22	11	3	1	44
2022	1					6	27	38	19	7	3	101
2023						1	20	72	50	13	3	159
2024	1		<mark>1</mark>									2
Grand Total	6	1	1	1	3	39	300	527	361	86	21	1346

BIRDS

Year	Months (only shown when data reported)											Cuand Tatal
	January	February	March	May	June	July	August	September	October	November	December	Grand Total
2013								1				1
2018							4	14	4	2		24
2019						2	13	35	4			54
2020									2			2
2021								8				8
2022	2	1			2	20	94	86	41	17	3	266
2023				1	3	18	82	96	50	11	5	266
2024	2	1	1									4
Grand Total	4	2	1	1	5	40	193	240	101	30	8	625

IT-WNF-2024-00001

- 12/01/2024 Confirmation
- Calabria
- Ag c-ELISA +, ELISA + horse
- · No suspicion, clinical signs
- · Vaccinated*

FR-WNF-2024-00001

- 11/04/2024 Confirmation
- Charente-Maritime
- ELISA IgM*+ horse
- No suspicion, healthy animal* (ADIS: clinical signs)

*info provided by IT-IZS and FR-ANSES

ES-WNF-2024-00001

- 23/01/2024 Confirmation
- Castilla y León
- Real-time PCR+ sparrow hawk
- No suspicion, no clinical signs

DE-WNF-2024-00001

- 23/01/2024 Confirmation
- Brandenburg
- Test not available Accipitridae
- No suspicion, no clinical signs

IT-WNF-2024-00002

- 09/02/2024 Confirmation
- Calabria
- Real-time PCR+ Common magpie
- No suspicion, clinical signs

IT-WNF-2024-00003

- 28/03/2024 Confirmation
- Piemonte
- · Real-time PCR+ Passer domesticus
- No suspicion, clinical signs







EFSA-Disease Profile West Nile fever

Living systematic literature review of **experimental WVV infections** in different animal species demonstrated **genome** detection for at least **7 weeks** in some bird species



Challenges of the WNV seasonal surveillance



The identification of the "risk area of locally acquired West Nile virus"



- The start of the transmission season is influenced by the
 - activity of Culex pipiens s.l.,
 - transmission cycle in the natural avian hosts,
 - WNV extrinsic period in the vectors.
 - → Influenced by the weather different in every year

Early, sporadic cases

- Laboratory diagnostic tests might not differentiate from an infection in the end of the previous season.
- Possible off-season WNV-infected mosquito bites (e.g., by overwintering *Cx. pipiens molestus* or hybrids).
- → Timely, detailed information is necessary for the assessment whether an "early" case is a signal for the early start of the season.
- → "Early" cases necessitate increased diagnostic awareness.





Acknowledgments

ECDC: Joana Haussig, Enrique Delgado, Liese van Gompel, Blanca Alonso, Mohammed Afzal, Olivier Briet, Celine Gossner

EFSA: Sofie Dhollander, Lina Mur, Frank Boelaert